[{"orgOrder":0,"company":"Biovian","sponsor":"ANL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"ANL-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biovian","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovian \/ Biovian","highestDevelopmentStatusID":"4","companyTruncated":"Biovian \/ Biovian"}]

Find Clinical Drug Pipeline Developments & Deals by Biovian

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufactu...

                          Brand Name : ANL-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 18, 2022

                          Lead Product(s) : ANL-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : ANL Bio

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank